Recently, Dr. Neal Shore was a presenter at American Society of Clinical Oncology (ASCO)’s annual meeting on Prevention, Risk Reduction and Hereditary Cancer.
Additionally, he was 1st author on 3 posters and co-author on numerous others:
Poster #1 – Phase 1b study of bavdegalutamide, an androgen receptor PROTACdegrader, combined with abiraterone in patients with metastatic prostate cancer. https://bit.ly/3H54Hmi
Poster #2 – Open-label study of androgen receptor inhibition with darolutamide plus androgen-deprivation therapy (ADT) versus ADT in men with metastatic hormone-sensitive prostate cancer using an external control arm (ARASEC). https://bit.ly/3H54Hmi
Poster #3 – A phase 3 study of the subcutaneous programmed cell death protein 1 inhibitor sasanlimab as single agent for patients with bacillus Calmette-Guérin, unresponsiv,e high-risk, non-muscle invasive bladder cancer: CREST Study Cohort B. https://bit.ly/3HbkBLV